ArticleCardiovascular and interventional radiology2025
Combined Percutaneous Sclerotherapy Plus Transarterial Embolization for Refractory Sports Injuries in Young Athletes: A Feasibility Study.
Article in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- We Saved the Best for Last….Cardiovascular and interventional radiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the feasibility and safety of combined percutaneous sclerotherapy plus transarterial embolization for refractory sports-related tendinopathy in young athletes. MATERIALS AND
methodsTwelve athletes with 20 lesions (13 Achilles tendinopathies, 6 patellar tendinopathies, 1 iliotibial band syndrome), suffering pain persisting >3 months despite conservative management were included. Ultrasound-guided foam sclerosant was injected into the peri-tendinous subcutaneous tissue at the most painful area until approximately 50% pain relief was achieved. Immediately after the sclerotherapy, angiography was performed, and hypervascular neovessels at the pain site were embolized with a mixture of iondinated contrast medium and Imipenem/Cilastatin. Visual analog scale (VAS) scores were measured and peri- and post-procedural adverse events were recorded.
resultsSclerosant injection produced an immediate ~50% pain reduction in all treated lesions, after which TAME was performed in 19 of 20 lesions (95%). Angiographic hypervascular staining was observed in 95% (19/20) of cases, facilitating targeted embolization. The mean sclerosant volume and imipenem amount were 1.4 ± 0.7 mL and 370.1 ± 14.9 mg, respectively. Mean VAS scores decreased from 6.7 ± 1.2 at baseline to 3.2 ± 1.1 at 1 week and 2.7 ± 0.8 at 6 months (p < 0.01). Clinical success was achieved in 18 of 20 lesions (90%), corresponding to 10 of 12 patients (83%). Minor complications occurred in 2 cases (2 groin hematomas), and all patients experienced mild post-injection soreness resolving within 4 days. No major complications or serious adverse events were observed.
conclusionThe combined sclerotherapy plus embolization technique is feasible and safe for treating refractory lower-extremity tendinopathies in young athletes. Comparative studies are needed to assess potential added benefits.
Indexed as
Identifiers
40653532What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.